Scholar Rock: Funding, Investors & Team (Oct 2026)
Scholar Rock is a biopharmaceutical company that specializes in discovering and developing groundbreaking medications for the treatment of severe diseases that involve protein growth factors. By gaining a greater understanding of how these growth factors activate, we have been able to create a unique platform for identifying and developing monoclonal antibodies that specifically target these signaling proteins at the cellular level. This strategy, which focuses on the disease microenvironment, aims to overcome previous challenges associated with inhibiting growth factors for therapeutic purposes. By concentrating on growth factors that have been scientifically proven to be biologically significant, we hope to streamline the development process. Our main product candidate, SRK-015, is a selective inhibitor that targets the activation of the growth factor myostatin in skeletal muscle for the treatment of spinal muscular atrophy (SMA). We anticipate starting Phase 1 clinical trials in the second quarter of 2018. Additionally, leveraging our proprietary platform, we are also working on creating a pipeline of innovative treatment options for other neuromuscular disorders, cancer, fibrosis, and anemia, with the potential to greatly improve the lives of patients suffering from these conditions.
Scholar Rock has raised $385M across 2 funding rounds on record, the most recent an undisclosed round of $300M announced in Oct 2024.
That round is above the $8.4M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Scholar Rock Company Profile and Key Stats
Latest funding round on record: Oct 2024.
Scholar Rock Funding Rounds
Scholar Rock raised $85.0M in an undisclosed round announced in Oct 2023.
1 years later, an undisclosed round of $300M was announced in Oct 2024.
Scholar Rock Founders and Leadership Team
No contact details are on record for this team yet.
Scholar Rock Funding Compared to Other Biotechnology Startups
Scholar Rock's latest round of $300M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Scholar Rock in Biotechnology and Cambridge
Companies Similar to Scholar Rock
Prolific Machines is a biotech company located in San Francisco, California, that was established in 2020. It…
Altay Therapeutics is a biotech company focused on finding and discovering small molecule therapies for…
Kallyope, we believe that the gut is the gateway to our internal world. Containing millions of neurons, the…
Astrocyte Pharmaceuticals is a drug development company that helps in the recovery and well-being of brain…
Tiny Health offers a gut health test specifically designed for mothers and babies aged 0 to 3 years.…
Junevity is dedicated to using cutting-edge transcription factor medicines to combat age-related diseases.…
Arkea Bio creates technology aimed at reducing greenhouse gas (GHG) emissions in the agricultural sector.
Serán is a contract development and manufacturing organization providing a comprehensive suite of…
Precision’s goal is to provide breakthrough treatments for the one billion patients worldwide suffering from…
Enveda is a biotechnology company that utilizes AI-powered tools to explore and characterize molecules from…
Avery Therapeutics, Inc. is a company dedicated to developing tissue engineered therapeutics to treat…
Scholar Rock Funding FAQs
What does Scholar Rock do?
Scholar Rock is a biopharmaceutical company that specializes in discovering and developing groundbreaking medications for the treatment of severe diseases that involve protein growth factors. By gaining a greater understanding of how these growth factors activate, we have been able to create a unique platform for identifying and developing monoclonal antibodies that specifically target these signaling proteins at the cellular level. This strategy, which focuses on the disease microenvironment, aims to overcome previous challenges associated with inhibiting growth factors for therapeutic purposes. By concentrating on growth factors that have been scientifically proven to be biologically significant, we hope to streamline the development process. Our main product candidate, SRK-015, is a selective inhibitor that targets the activation of the growth factor myostatin in skeletal muscle for the treatment of spinal muscular atrophy (SMA). We anticipate starting Phase 1 clinical trials in the second quarter of 2018. Additionally, leveraging our proprietary platform, we are also working on creating a pipeline of innovative treatment options for other neuromuscular disorders, cancer, fibrosis, and anemia, with the potential to greatly improve the lives of patients suffering from these conditions.
How much funding has Scholar Rock raised?
Scholar Rock has raised $385M across 2 rounds on record. The most recent is an undisclosed round of $300M announced in Oct 2024.
When did Scholar Rock last raise funding?
Scholar Rock's most recent funding round on record is an undisclosed round of $300M, announced in Oct 2024.
Who founded Scholar Rock?
FundedIQ lists Nagesh K Mahanthappa (Founder) at Scholar Rock.
Where is Scholar Rock headquartered?
Scholar Rock is based in Cambridge, Massachusetts, United States.
How many employees does Scholar Rock have?
Scholar Rock is in the 101-250 employee band.
How does Scholar Rock's funding compare to other Biotechnology startups?
Scholar Rock's latest round of $300M is above the $8.4M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.
About FundedIQ's Scholar Rock Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Scholar Rock is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.